Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Amgen Reclaims Rights From GSK To Grow In Ex-US Markets

This article was originally published in Scrip

Executive Summary

Amgen Inc. will reacquire ex-US rights to its cancer drug Vectibix (panitumumab) and bone drugs Prolia (denosumab) and Xgeva (denosumab) in 48 countries from GlaxoSmithKline PLC, which generated $111m in combined revenue from the products in 2014.

Advertisement

Related Content

Amgen-Dr Reddy's Build On India Alliance

Topics

Advertisement
UsernamePublicRestriction

Register